• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002332.SZ
Share

Zhejiang Xianju Pharmaceutical Co., Ltd. Stocks

CN¥ 8.43Last Updated 14.07.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.20B

CN¥ 8.43
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Xianju Pharmaceutical Co.,Ltd. is a global enterprise specializing in the production and distribution of steroidal and hormonal pharmaceutical products. Its offerings span active pharmaceutical ingredients (APIs), specifically steroid-based medications and both male and female hormones, alongside various chemical intermediates. The company also provides a comprehensive selection of finished dosage forms, including tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-for-injection preparations. Established in 1972, Zhejiang Xianju Pharmaceutical Co.,Ltd. operates from its headquarters in Xianju, China.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of f

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of 002332.SZ is 11.2 and suggests 35.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 15:48

Morning in New York: News Flow Will Drive Volatility

14.07.2026 14:41

Shares of a small-cap AI solutions developer soared amid a sector-wide slump. Why?

14.07.2026 13:30

Risks for a neobank: Can Revolut Reach a $200 Billion Valuation?

14.07.2026 12:58

Following SK Hynix, Samsung has approved the listing of its securities in the U.S. — Bloomberg

14.07.2026 12:20

DeepSeek Founder Is Now the Richest AI Model Developer — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026